Teva launches generic Xeloda tablets

JERUSALEM — Teva Pharmaceutical Industries will launch the generic version of Xeloda (capecitabine) tablets, 150 mg and 500 mg, in the United States. The drug is used to treat cancers that have metastasized.



Xeloda tablets, 150 mg and 500 mg had annual sales in the United States of approximately $754 million as of December 2013, according to IMS.